Shots:
- Biocon Biologics has entered into strategic collaboration agreement with Civica to extend access & affordability of Insulin Aspart in the US
- As per the deal, Biocon will supply Insulin Aspart drug substance to Civica, which will manufacture prefilled pens & vials of insulin at its Petersburg, Virginia facility. Civica will commercialize it in the US post-development & trials, with no technology transfer involved
- Additionally, Biocon’s insulin aspart drug product is under the US FDA review
Ref: Biocon Biologics & Civica | Image: Biocon Biologics & Civica
Related News:- Biocon Biologics Launches Yesintek (Biosimilar, Stelara) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
